Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026
REDWOOD CITY, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced encouraging updated results from the Phase 1/2 RMC-GI-102 open-label study evaluating RASONQUE (daraxonrasib) in combination with gemcitabine and nab-paclitaxel (GnP) as…
REDWOOD CITY, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced encouraging updated results from the Phase 1/2 RMC-GI-102 open-label study evaluating RASONQUE (daraxonrasib) in combination with gemcitabine and nab-paclitaxel (GnP) as a potential first-line treatment for patients with metastatic pancreatic adenocarcinoma (PDAC). The data will be presented today during a late-breaking oral session at the EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
Independent home-product comparison website recognized for answer-first buying guides with clear best-overall picks, side-by-side spec tables and named trade-offs Independent home-product comparison website recognized for answer-first buying guides with clear best-overall picks, side-by-side spec tables and named trade-offs ...
NEW YORK, Nov. 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, both dates inclusive (the “Class Period”), of the important December 28, 2026 lead plaintiff deadline. ...
NORTH PLAINS, Ore., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Jewett-Cameron Trading Company Ltd. (the "Company"; Nasdaq: JCTC), a company committed to innovative products that enrich outdoor spaces, today announced operational and financial results for its fiscal year 2026 ended August 31, 2026. ...
NEW YORK, Nov. 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of CVRx, Inc. (NASDAQ: CVRX) between July 25, 2023 and August 6, 2026, inclusive (the “Class Period”), of the important January 8, 2027 lead plaintiff deadline. ...